If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Inc. DGX. Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #4 (Sell) but that could change following its mixed third quarter 2015 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.27 per share over the last 90 days. Quest Diagnostics adjusted earnings per share of $1.28 exceeds this estimate by a penny and increased 6.7% on a year-over-year basis.
Revenues: Quest Diagnostics posted revenues of $1.88 billion, marginally short of the Zacks Consensus Estimate which stood at $1.89 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, decreased 0.2% versus the prior year’s volume. Revenue per requisition grew by approximately 0.2%.
Major Factors: For 2015, the company expects revenues to peg at approximately $7.49 billion. Adjusted EPS is expected to be in the band of $4.75–$4.80.
Stock Price: Following the earnings release, there was no share price movement.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment